Low-dose tamoxifen halves recurrence of in situ breast cancer
The finding is practice-changing for women who are unable to tolerate the full dose, says researcher
Tamoxifen at a low dose reduces local and contralateral recurrence of breast intraepithelial neoplasia, according to a new randomised controlled trial.
Italian researchers randomly assigned 500 women aged 75 or younger with in situ breast cancers to receive tamoxifen 5mg or placebo for three years after surgery.
